Oncternal Therapeutics, Inc. ONCT
Set alert
At close · Dec 2
52-week range unavailable
- Open
- 0.70
- Prev close
- 0.5266
- Mkt cap
- 1.56M
- Vol
- 644.13K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5266
- High
- 0.70
- Forward P/E
- -0.05
- Beta
- 0.00
- Short ratio
- 0.09
- Inst. own
- 12.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2024
- 50-d avg
- 1.06
- 200-d avg
- 5.13
- 1y target
- 2.00
Key statistics
- Market cap
- 1.56M
- Enterprise value
- -12.83M
- Trailing P/E
- 0.00
- Forward P/E
- -0.05
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 0.17
- EPS (TTM)
- -11.69
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.16M
- Revenue growth
- 176.00%
- Free cash flow
- -17.68M
- Total cash
- 14.58M
- Total debt
- 191.00K
- Return on equity
- -149.86%
- Shares outstanding
- 2.96M
- Short % of float
- 0.50%
- 50-day average
- 1.06
- 200-day average
- 5.13
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 6, 2024
Expected Nov 6, 2024. Consensus EPS estimate -3.47.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -3.22 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -3.03 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -2.88 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -3.09 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -3.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -3.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jan 29, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oncternal.com
News
- Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
- Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
- Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
- Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
- Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
- Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
- Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
- Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Your note
Sign in to keep a note on ONCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREITMEYER JAMES B | Chief Executive Officer | Purchase | Apr 13, 2023 | 0 |
| HALE DAVID F | Director | Purchase | Feb 22, 2024 | 0 |
| KAUFMANN GUNNAR F | Officer | Purchase | Jun 13, 2023 | 94,726 |
| LEAVITT CHASE C. | General Counsel | Purchase | Apr 12, 2023 | 106,901 |
| VINCENT RICHARD G. | Chief Financial Officer | Purchase | Apr 12, 2023 | 163,219 |
| WILLS ROBERT JAMES | Director | Purchase | Apr 7, 2024 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.73% | 139,884 | 73.66K | Sep 29, 2024 |
| Millennium Management Llc | 2.07% | 61,205 | 32.23K | Sep 29, 2024 |
| Blackrock Inc. | 1.34% | 39,706 | 20.91K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 25,879 | 13.63K | Sep 29, 2024 |
| Pasadena Private Wealth, LLC | 0.84% | 25,000 | 13.16K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.60% | 17,905 | 9.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.65% | 107,989 | 56.87K | Jun 29, 2024 |
| Vanguard Extended Market Index Fund | 1.05% | 31,061 | 16.36K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.51% | 15,005 | 7.90K | Sep 29, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.49% | 14,404 | 7.58K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Small Cap ETF | 0.30% | 8,864 | 4.67K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 4,027 | 2.12K | Sep 29, 2024 |